Velico expands global manufacturing to meet demand for its FrontlineODP™ system, a technology enabling blood centers to produce life-saving dried plasma in 30 minutes. Learn how this innovation aims to transform trauma care.
BEVERLY, Mass. – In a significant move for global emergency medicine Velico Medical has announced a major expansion of its manufacturing and supply chain operations. The drive behind this growth? Soaring demand for the company’s groundbreaking FrontlineODP™ Spray Dried Plasma Manufacturing System—a technology designed to put life-saving care directly in the hands of first responders.
For years, a critical challenge in treating severe bleeding especially in remote or combat settings has been the storage and transport of plasma a vital blood product used for transfusion. Traditional frozen plasma requires a complex cold chain limiting its availability at the critical “point of injury.”
Turning Liquid to Powder, Transforming Trauma Care
The FrontlineODP™ system tackles this problem head-on. It’s designed to allow both military and civilian blood centers to transform liquid donor plasma into a dried, powdered form in just 30 minutes.
This dried plasma is a game-changer. It’s stored in an ultra-lightweight plastic bag, requires no refrigeration, and boasts a shelf life of up to two years. When a patient is in crisis, a medic can rehydrate the plasma in under three minutes, enabling immediate, life-saving transfusion directly at the scene.
Building a Global Network to Stop Bleeding
Velico’s vision is to create a decentralized manufacturing network. Instead of one central plant, hundreds of blood centers worldwide could use the FrontlineODP™ system to produce tens of thousands of dried plasma units annually. This model is gaining traction, with planned adoption accelerating across North America, Europe, and the Indo-Pacific. Combined production from existing and contracted systems is already projected to exceed 100,000 units per year.
To support this global push, Velico is now finalizing plans for new, fully automated production facilities dedicated to manufacturing the system’s consumables for the European and Indo-Pacific markets. Each facility is expected to have an annual capacity of 250,000 units. When combined with the company’s two U.S. facilities, Velico’s total manufacturing footprint will be capable of supporting nearly one million units of spray-dried plasma per year.
Leadership on a Life-Saving Mission
“For years, Velico has invested heavily in research and development to deliver mass availability of life-saving dried plasma,” said Richard Meehan, President & CEO of Velico. “As global adoption accelerates, we are scaling our manufacturing capabilities to meet unprecedented demand and help reduce deaths from hemorrhage worldwide.”
Andrew Racicot, Velico’s recently appointed Vice President of Manufacturing, emphasized the operational goal: “Expanding our global manufacturing footprint strengthens Velico’s ability to deliver with efficiency, consistency, and quality, ensuring life-saving plasma is available when and where it’s needed most.”
Important Note for Readers:
The FrontlineODP™ Spray Dried Plasma System is currently an investigational device and has not yet received regulatory approval for commercial use. It is limited by law to investigational use. Regulatory requirements will determine its future approval and market availability in different countries.
Velico’s development program has been supported with federal funds from the Biomedical Advanced Research and Development Authority (BARDA).
About Velico:
Velico is a private medical technology company based in Beverly, Massachusetts, with a mission to eliminate preventable death from bleeding. The company is building partnerships with blood centers, trauma surgeons, and first responders worldwide to advance its technology.
Article Source and Credit :- https://www.prnewswire.com/news-releases/velico-announces-major-expansion-of-manufacturing-and-supply-chain-operations-302618886.html